The Cannabis Investing Podcast

When will capital markets catch up to the psychedelic industry? Ronan Levy, CEO and Co-Founder of Field Trip, discusses strategy behind focusing on ketamine assisted therapy and why splitting up Reunion Neuroscience (REUN) (drug development) and Field Trip (FTHWF) (clinical infrastructure) made the most sense ('The FDA likes things in neat tidy boxes'). Adult-use psychedelic market has already begun - differentiation will be an issue. In this time of decimated valuations, what should investors focus on?Our links:The Cannabis Investing Podcast: https://seekingalpha.com/cannabisinvestingpodcastOn The Cannabis Investing Podcast, host Rena Sherbill provides actionable investment insight and the context with which to understand the burgeoning cannabis industry.Seeking Alpha Premium: https://seekingalpha.com/premium/getting-startedA comprehensive set of features and analysis that helps take the guesswork out of your investing decisions. Get the bottom-line on any stock or ETF with our Premium tools.Alpha Picks: https://seekingalpha.com/alpha-picks/subscribeAlpha Picks gives you two top stock picks each month, sifted from Seeking Alpha's analysis of thousands of stocks. We do the work. You reap the rewards.Twitter: https://twitter.com/canpod1IG: https://www.instagram.com/cannabisinvestingpodcast/Show links:Field Trip Health: https://www.fieldtriphealth.com/Field Trip Twitter: https://twitter.com/fieldtriphealthField Trip IG: https://www.instagram.com/fieldtriphealth/?hl=enRonan Levy Twitter: https://twitter.com/RonanDLevyRonan Levy IG: https://www.instagram.com/ronandlevy/Ronan's 1st appearance: https://www.spreaker.com/user/16831773/shifting-focus-from-cannabis-to-other-ca

How should cannabis investors ride the wave of depressed valuations? Tiby Erdely, who came to cannabis from Goldman Sachs and co-founded KEY Investment Partners, talks about why consolidation is coming. We also discuss why investors should get deep into companies' income statements and balance sheets and focus primarily on the last 6-12 months of performance. Why the top 5 multi-state operators (Trulieve (TCNNF), Green Thumb Industries (GTBIF), Curaleaf (CURLF), Cresco (CRLBF), and Verano (VRNOF)) are separating from the pack. Canopy Growth (CGC) and Tilray (TLRY): Canadian operators' U.S. intentions - keep a close eye on Nasdaq setting a precedent.Our links:The Cannabis Investing Podcast: https://seekingalpha.com/cannabisinvestingpodcastOn The Cannabis Investing Podcast, host Rena Sherbill provides actionable investment insight and the context with which to understand the burgeoning cannabis industry.Seeking Alpha Premium: https://seekingalpha.com/premium/getting-startedA comprehensive set of features and analysis that helps take the guesswork out of your investing decisions. Get the bottom-line on any stock or ETF with our Premium tools.Alpha Picks: https://seekingalpha.com/alpha-picks/subscribeAlpha Picks gives you two top stock picks each month, sifted from Seeking Alpha's analysis of thousands of stocks. We do the work. You reap the rewards.Twitter: https://twitter.com/canpod1IG: https://www.instagram.com/cannabisinvestingpodcast/Show links:KEY Investment Partners: https://keyinvestmentpartners.com/

As the industry develops, lots of talk recently around cannabis consumption lounges and cannabis tourism in Colorado, Nevada and beyond. What it's like to grow the cannabis economy with Chris Chiari, CEO/Founder of The 420 Hotels. Cannabis is a commodity - what that means for pricing and business models.Our links:The Cannabis Investing Podcast: https://seekingalpha.com/cannabisinvestingpodcastOn The Cannabis Investing Podcast, host Rena Sherbill provides actionable investment insight and the context with which to understand the burgeoning cannabis industry.Seeking Alpha Premium: https://seekingalpha.com/premium/getting-startedA comprehensive set of features and analysis that helps take the guesswork out of your investing decisions. Get the bottom-line on any stock or ETF with our Premium tools.Alpha Picks: https://seekingalpha.com/alpha-picks/subscribeAlpha Picks gives you two top stock picks each month, sifted from Seeking Alpha's analysis of thousands of stocks. We do the work. You reap the rewards.Twitter: https://twitter.com/canpod1IG: https://www.instagram.com/cannabisinvestingpodcast/Show links:The 420 Hotels: https://the420hotels.com/home

Stephen Tobin on investing in psychedelic stocks while they're still pre-revenue. Why he's a big believer in Compass Pathways (CMPS) and Atai Life Sciences (ATAI) and not as much in Cybin (CYBN) or MindMed (MNMD). Will first-movers get the advantage? What will move share prices? The importance of patents and cash in the industry.

Legal cannabis has officially hit New York. Two long-time advocates, Allan Gandelman and Kaelan Castetter, came on when New York first went legal and return to provide context for this moment. We discuss when supply might meet demand, why the two-tier system works and will likely be a federal model, the illicit market, and the obscene value of NY licenses.

What makes a psychedelic company compelling? Analyst Alex Carchidi has a background in biotech and focuses on long-term growth and risk management. He shares what investors should focus on in the psychedelic space and the pros and cons of owning his top 5 psychedelic stocks.

Negative conditions are crashing down all around investors. Make sure companies in your portfolio will survive. Ted Waller shares why some stocks are falling off a cliff. Not all ETFs are created equal - stay away from the leveraged ETFs ('dynamite ready to be lit'). Pinning hopes on current cannabis leaders. Cash flow is extremely important.

James Baker and Julian Lin are two standout analysts who have joined us over the years for 3 MasterClasses in cannabis investing. This is a compilation of highlights from those shows. As the last episode of the year, and as we've been met with more political gridlock and disappointment, we would do well to remind ourselves of some investing truths, let go of outdated hopes and focus more on descheduling than banking reform. On the crash that came, uplisting, internal and external growth, goodwill and intangible assets and why cash flow is more important than adjusted EBITDA.

Welcome to the 2nd episode of Psychedelic Sunday, where we delve into psychedelics and investing. Today we give an overview of the 4 main stocks in psychedelics, focusing on recent earnings calls and analyst Q&A for Compass Pathways (CMPS), Atai Life Sciences (ATAI), MindMed (MNMD) and Cybin (CYBN). We'll be diving even deeper into these stocks over the next couple of weeks with the help of Stephen Tobin and Alexander Carchidi.

Celebrating episode 200 with Emily Paxhia! Time to reset expectations and focus the conversation on rescheduling (or descheduling!) cannabis. Dysfunction at the federal level - not passing cannabis banking reform is in direct opposition to majority of US voters. Sidestepping the froth with the PSDN ETF. Small cap value story. Top companies already positioned for uplisting, but what are the rules of the game? Resigning from Ascend Wellness Board, addressing the rumors. Advice and support for retail investors.

Welcome to the first ever Psychedelic Sunday episode! There is a lot of overlap between cannabinoid and psychedelic experiences and today we launch our coverage of the psychedelics industry. Challenges and opportunities within psychedelics; highlighting four stocks: Compass Pathways (NASDAQ:CMPS), Cybin (NYSE:CYBN), Atai Life Sciences (NASDAQ:ATAI), and MindMed (NASDAQ:MNMD).

How should you build your cannabis portfolio? Analyst Jesse Redmond shares his thoughts on MSOs, ETFs and smaller players. Green Thumb resignations, stepping away from Ascend. California, New Jersey and the obligatory SAFE discussion. His favorite strains and why he grows his own cannabis.

With tech stocks crashing, are cannabis stocks the most compelling investment right now? Julian Lin tells investors to focus on MSOs that can generate free cash flow right now. Price compression has been far more severe than expected. What rising interest rates means for the cannabis industry. Why Julian's so bullish on NewLake Capital. 

Fairly disappointing news out of the US as only 2 of the 5 states that had adult-use cannabis on the ballots passed it. With Biden's recent promises amid a protracted regulatory process, will investors' and activists' frustration lead to change? What we as investors can look forward to in the industry.

Glass House aims to be free cash flow positive. Co-Founder and President Graham Farrar comes back to discuss the opportunity and challenge in fighting its main competition - California's illicit market. We also discuss why he thinks Biden's recent announcements are more strategy than stunt and why Glass House won't be at MJBizCon.

Will cannabis get rescheduled or descheduled? BDSA CEO Roy Bingham discusses why the implications of that answer are dramatic. Conducting market research and data for the cannabis industry, state by state legalization, development of the illicit market and its lack of consequences. Why he's cautious about the international market. 

Agrify (AGFY) CEO Raymond Chang joined me last year to discuss indoor vertical farming. We recorded this interview before Agrify's recent stock split, but we do discuss the current challenging environment and the pivot the company is now focused on. Rapid deployment, the necessity for consistency, addressing industry pain points and growing segments.

Entourage Effect Capital Founder and StateHouse (STHZF) Chairman Matt Hawkins returns to discuss cautiously hunting for distressed assets, the transformative outlook of new regions going legal and developing legislation. Private equity, institutional capital wanting in on cannabis.

Weedmaps (MAPS) CEO Chris Beals came on Seeking Alpha earlier this year after its Sprouts acquisition. He joined me recently at Benzinga's Cannabis Capital Conference to discuss scaling a cannabis marketplace. The arduous task of policing the platform, whether brand loyalty really exists and the catalyst that people aren't talking about.

Chief Investment Officer Aaron Miles shares why Verano (VRNOF) got dinged when it went public and how it's shaping its strategy as the market continues to develop. We discuss the Goodness Growth (GDNSF) acquisition, New York's protracted timeline and investing dollars at the right time. One of the top MSOs, find out why Seeking Alpha authors and Wall Street analysts rate Verano as a Strong Buy and why momentum is a concern.

Live from Chicago's Benzinga Cannabis Capital Conference with Fast Money's Tim Seymour! Why MSOs are still the most interesting investments but some are separating from others. Tim's conversation with Boris Jordan. Oversupply in the market. People aren't as optimistic and why that's a good thing.

Talking cannabis flower usage and pre-rolls with Lowell Farms' Chairman George Allen. The developing retail picture, competitive form factors and the maturing consumer. Lowell's new 35s, bringing elegance to joints and making sense of the industry.

Talking cannabis legalization in Germany with Niklas Kouparanis, CEO and Co-Founder of Bloomwell Group - Germany's largest cannabis company. We talk about legalizing the whole value chain. The mistake of decriminalizing before legalizing. Learning the lessons from already legal markets.

Coming from blue chip CPG companies like Clorox, Troy Datcher came on board as CEO for TPCO Holding (GRAMF) last year. Troy said that he's longed to have a relationship this intimate with the consumer in previous industries. "Candidly, I didn't own the experience." In cannabis TPCO reaches about 70% of California consumers. Creating a different company from how it started. Encouraged by legislative changes in California, but it's not enough. For those that can, influence the outcome.

Spending more time on the California cannabis market with Lauren Fontein, one of the founders of The Artist Tree, a beautiful new consumption lounge in West Hollywood and Courtney Caron, an instrumental part of the developing retail picture in California. This week we sat on the lounge's balcony and discussed the baby steps happening in the cannabis industry, what retail consumption looks like, and what's holding the state - and country - back from real growth.

Emily Paxhia and Hirsh Jain return to catch us up on the California cannabis market and beyond. Getting out of the death spiral but not quite out of the woods yet. Elimination of cultivation tax, but other taxes remain. Incremental progress, but is California moving in the right direction? What parts of the supply chain will benefit? Cannabis pricing, legal vs illicit. Moving towards commoditization.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Jon DeCourcey shares how his cannabis investing philosophy has shifted over the past few months. Micro vs macro perspective, risk on vs risk off environment. What is going on in Washington? Is there reason for more optimism on political front? Moving pieces of continued cannabis expansion and what's happening beyond companies' control. Learn more about your ad choices. Visit megaphone.fm/adchoices

Happy to have Alan Brochstein back! Thoughts on the recent rally (less about Bulls buying than Bears covering), political doubts and overall optimism. Valuations are low, but there's good news across the States. These stocks are really cheap. Mistake to assume margins will go down. Analyzing Canopy Growth (CGC), Curaleaf (CURLF), AYR Wellness (AYRWF), Ascend (AAWH) and more. Learn more about your ad choices. Visit megaphone.fm/adchoices

Alan Sumler comes from the world of academia. We discuss his long positions in cannabis and how he approaches his stock analysis. How history influences his cannabis investing and looking at short-term movements through a long-term lens. A rare opinion - Positive on Canada! Playing options, balancing technical and fundamental analysis and problems with the way we cover cannabis investing. Learn more about your ad choices. Visit megaphone.fm/adchoices

Brad Thomas, who runs iREIT on Alpha, breaks down why cannabis REITs are an income play and a growth story. Lack of federal legalization affords cannabis REITs a strong opportunity as real estate is a big part of the industry. We discuss the value of licenses, leases, good and bad tenants. Brad's bullishness on Innovative Industrial Properties (IIPR), as well as NewLake Capital (NLCP), AFC Gamma (AFCG) and Power REIT (PW). Learn more about your ad choices. Visit megaphone.fm/adchoices

Catching up on the cannabis industry, we revisit some of our most salient analysis of the past 6 months. Jon DeCourcey covers upcoming tailwinds; Jason Powers and Julian Lin talk valuations and compare undervalued tech to cannabis and Nick Gastevich discusses returning to former growth rates as more states come online. Learn more about your ad choices. Visit megaphone.fm/adchoices

Ted Waller joins us again to discuss staying bullish but getting more realistic about the cannabis industry. Limited growth rates, margin compression and the need to keep our emotions out of investing. Buying special situations and what stocks are more concerning. Learn more about your ad choices. Visit megaphone.fm/adchoices

Julian Lin, founder of Cannabis Growth Investor, returns to discuss two of his favorite cannabis plays - a REIT and an MSO. Cannabis investing philosophy (valuations should drive capital allocations). Net leases, cap rates and how legislation may affect bullish thesis. Smart acquisitions, management compensation, inside ownership and understanding high debt. Learn more about your ad choices. Visit megaphone.fm/adchoices

With Ascend Wellness - and perhaps other MSOs - set to sue the US government, we think it's a good time to hear directly from cannabis executives to get their thoughts on the industry. We hear from TerrAscend 's Jason Wild, Ascend Wellness' Abner Kurtin, MariMed's Bob Fireman and Weedmaps' Chris Beals. As we hit mid-year, we hope this brings you more clarity into understanding the sector! Learn more about your ad choices. Visit megaphone.fm/adchoices

Capital is disappearing in the cannabis industry. Mike Regan and Colin Ferrian return and we discuss what investors need to understand about valuations (it's not just like tech). Grading California's main players, consumption patterns, price erosion. EBIDA over EBITDA. For a real transparent take on California trends, listen to Scotts Miracle-Gro conference call every quarter. Cyclical trends amidst secular growth and Colin turns the tables on me! Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Robin Goldstein and Professor Daniel Sumner wrote Can Legal Weed Win?: The Blunt Realities of Cannabis Economics, an objective take on understanding the long-term economics of legal and illicit cannabis. Competition between legal and illicit market - not clear who wins. What types of policies will help legal weed win, learning from other commodity markets and why having a cash cushion is essential. The benefits of being a craft brand and why regional identity is key. Learn more about your ad choices. Visit megaphone.fm/adchoices

Patience, more institutional capital and more catalysts, but mostly we need patience as we wait for the industry to grow into a more mature sector. Matt Hawkins returns to discuss StateHouse/Harborside, the California cannabis market and the developing US landscape. Advice to retail investors and why managing cash is key. Institutional capital will come in and everyone will want in on an MSO or wanting to partner with an MSO. That's where the money is going to be made. Learn more about your ad choices. Visit megaphone.fm/adchoices

Michael Auerbach, Founder and Chairman of Subversive Capital and The Parent Company (OTCQX:GRAMF) first came on for our first two SPAC Weeks and returns today to update us on GRAMF and the growth that hasn't shown up the way we expected. InterCure and the Israeli market. We also discuss his new ETF PUNK, which came on the scene and shorted Meta. Learn more about your ad choices. Visit megaphone.fm/adchoices

Julian Lin catches us up on recent earnings volatility, valuations and how investors should be looking at the cannabis industry. Why he's a big fan of Verano but not a fan of the Cresco/Columbia Care merger. IIPR, NewLake Capital and why cannabis REITs are highly compelling. Learn more about your ad choices. Visit megaphone.fm/adchoices

4/20 is a time to celebrate the plant and industry but also a time to reflect on how much further we still need to go. Growing up in a farming family, Reginald Stanfield started JustinCredible Cultivation, the first non-equity, Black-Owned Cannabis Cultivation in Massachusetts. We discuss the two different cannabis industries; working with Curaleaf, navigating the challenges of raising capital, evolving regulations and reasons for optimism.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Jon DeCourcey from Viridian Capital Advisors returns to discuss recent earnings and why disappointment is overblown. Favoring quality, underappreciated names in the cannabis industry due to favorable fundamentals and growth opportunities. These names also benefit from consolidation in the space at a time where it's hard to find alpha in the sector. Learn more about your ad choices. Visit megaphone.fm/adchoices

Guy Rocourt is President, CEO and co-founder of Papa & Barkley, a pillar of California cannabis brands set to roll out nationally this year and recently joined Christian Cannabis. Pushing back on problematic corporate cannabis. Building a brand with solventless sustainable products. Why many MSOs aren't in California - a branding knife fight. Normalizing cannabis - if you use cannabis, say something. Learn more about your ad choices. Visit megaphone.fm/adchoices

Nick Gastevich, one of our favorite commenters on Seeking Alpha, returns to the show to catch us up on the state of cannabis investing. Recent earnings, effects from macro pressures, and how Nick looks at recent consolidations. Illinois' social equity program had the right idea but large MSOs have had too much of a head start. Wave of new states legalizing cannabis now especially important in the face of long federal delays. Learn more about your ad choices. Visit megaphone.fm/adchoices

Tim Seymour returns to talk cannabis investing within current market conditions. Interconnectivity between asset classes in the time of war and geopolitical volatility. Legislative process, wholesale prices, compression and recent cannabis earnings. Cannabis IPOs, ETFs and looking for free cash flow generation. Learn more about your ad choices. Visit megaphone.fm/adchoices

Alisia Ratliff is CEO of Victus Capital Ventures and returns again on International Women's Day to discuss the European cannabis markets, what has Alisia excited about the scientific and business breakthroughs in the industry and pursuing a more equitable path in the industry. Learn more about your ad choices. Visit megaphone.fm/adchoices